Does Rallies show Form 4 insider transactions for SILO?

Yes. Rallies tracks SILO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is SILO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SILO. It does not provide personalized investment advice.

SILO (Silo Pharma, Inc. Common Stock) Stock Analysis - Insider Trades

Silo Pharma, Inc. Common Stock (SILO) is a publicly traded Healthcare sector company. As of May 21, 2026, SILO trades at $0.37 with a market cap of $6.31M and a P/E ratio of -0.76. SILO moved -0.13% today. Year to date, SILO is +5.20%; over the trailing twelve months it is -23.78%. Its 52-week range spans $0.22 to $3.37. Rallies surfaces SILO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading SILO stock inside the company?

Recent SILO insider activity includes Weisblum Eric bought 2.50K, Weisblum Eric bought 2.50K, Weisblum Eric bought 1.00K, Weisblum Eric bought 1.00K, and Weisblum Eric bought 4.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

SILO Key Metrics

Key financial metrics for SILO
Metric	Value
Price	$0.37
Market Cap	$6.31M
P/E Ratio	-0.76
EPS	$-0.50
Dividend Yield	0.00%
52-Week High	$3.37
52-Week Low	$0.22
Volume	0
Avg Volume	0
Revenue (TTM)	$72.10K
Net Income	$-4.23M
Gross Margin	38.57%

Recent SILO Insider Trades

Weisblum Eric bought 2.50K (~$1.02K) on Dec 15, 2025.
Weisblum Eric bought 2.50K (~$1.05K) on Dec 15, 2025.
Weisblum Eric bought 1.00K (~$365) on Nov 21, 2025.
Weisblum Eric bought 1.00K (~$370) on Nov 20, 2025.
Weisblum Eric bought 4.50K (~$1.82K) on Nov 19, 2025.

Latest SILO News

Silo Pharma Seeks Patent for Ibogaine TBI Therapy in $6B Market — May 7, 2026
SNDL Q1 Revenue Drops 4.4% with $9.1M Loss; Vireo to Acquire FLUENT — May 4, 2026
FDA Grants Noribogaine IND and ARPA-H Awards Validate Silo Pharma’s PTSD Program — Apr 29, 2026
Silo Pharma Buys Qwikagents.ai, Targets $47–$53B AI Agent Market — Apr 22, 2026
Silo Pharma’s SPC-15 Intranasal PTSD Program Advances Under 505(b)(2) Pathway After Executive Order — Apr 20, 2026

SILO Analyst Consensus

SILO analyst coverage data. Average price target: $0.00.

Common questions about SILO

Who is trading SILO stock inside the company?: Recent SILO insider activity includes Weisblum Eric bought 2.50K, Weisblum Eric bought 2.50K, Weisblum Eric bought 1.00K, Weisblum Eric bought 1.00K, and Weisblum Eric bought 4.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for SILO?: Yes. Rallies tracks SILO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is SILO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SILO. It does not provide personalized investment advice.